BioMarin consolidates staff at Amicus HQ after closing $4.8B deal for rare disease peer

Shortly after locking down its $4.8 billion deal for rare disease compatriot Amicus Therapeutics, BioMarin Pharmaceutical is consolidating the workforce tied to the acquired company’s headquarters Shortly after locking down its $4.8 billion deal for rare disease compatriot Amicus Therapeutics, BioMarin is consolidating the workforce tied to the acquired company’s headquarters in New Jersey Pharma Vaccines Asia Cell & Gene Therapy Drug Delivery Executives Manufacturing Facilities Recalls Warning Letters Marketing Special Reports Fierce 50 Special Report Awards Gala Trending Oncology Supply Chain AI and Machine Learning Awards Outsourcing Awards Innovation Awards Pharma Marketing Awards Resources Podcasts Fierce Events Industry…

Fraiser Kansteiner · 2026-05-12

Shortly after locking down its $4.8 billion deal for rare disease compatriot Amicus Therapeutics, BioMarin is consolidating the workforce tied to the acquired company’s headquarters in New Jersey

Source: FiercePharma